Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research report issued on Wednesday, Benzinga reports. They presently have a $15.00 target price on the biotechnology company’s stock. Wedbush’s target price indicates a potential upside of 339.88% from the stock’s previous close. A number […]

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was upgraded by research analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, MarketBeat reports. The firm presently has a $9.00 target price on the biotechnology company’s stock. Needham & Company LLC’s price target […]